Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Operating Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Operating Margin for 4 consecutive years, with 67.95% as the latest value for Q1 2025.

  • On a quarterly basis, Operating Margin rose 372982.0% to 67.95% in Q1 2025 year-over-year; TTM through Sep 2025 was 29.91%, a 535613.0% increase, with the full-year FY2024 number at 2096.48%, up 446039.0% from a year prior.
  • Operating Margin was 67.95% for Q1 2025 at Century Therapeutics, up from 893.46% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 67.95% in Q1 2025 to a low of 35431.31% in Q2 2023.
  • A 4-year average of 8053.42% and a median of 3661.87% in 2024 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: crashed -3318554bps in 2023, then soared 3092353bps in 2024.
  • Century Therapeutics' Operating Margin stood at 6392.71% in 2022, then crashed by -155bps to 16329.1% in 2023, then skyrocketed by 95bps to 893.46% in 2024, then soared by 108bps to 67.95% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Operating Margin are 67.95% (Q1 2025), 893.46% (Q4 2024), and 4398.1% (Q3 2024).